

# Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs  
and Drug Control

MUSCAT



سِلاطِنَا عُمَانِ  
وَزَارَةُ الصِّحَّةِ  
المديرية العامة للصحة  
والرقابة الدوائية  
مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES  
Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)  
Director General of Royal Hospital  
Director General of Khoula Hospital  
Director General of Medical Supplies (MOH)  
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)  
Director General of Quality Assurance Centre, MOH  
Director General of Disease Surveillance & Control, MOH  
Director General of Primary Healthcare, MOH  
Director General of Nursing Affairs, MOH  
Director General of Specialised Medical Care, MOH  
Hospital Director (Al Nahda Hospital)  
Hospital Director (Al Massara Hospital)  
The Head of Medical Services in SQU Hospital  
The Head of Medical Services in Royal Oman Police  
The Head of Medical Services in Ministry of Defence  
The Head of Medical Services in The Diwan  
The Head of Medical Services in The Sultan's Special Force  
The Head of Medical Services in Internal Security Services  
The Head of Medical Services in Petroleum Development of Oman  
The Head of Medical Services in LNG Oman  
ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No. 149/2020 dated 20/8/2020  
regarding the Half Yearly PV Report for the period January to June 2020.

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Director of Medical Device Control, DGPA&DC
- Supdt. of Central Drug Information
- SH (PV of Human Medicine)
- SH (PV of Herbal Medicine)
- Head of Cordin & FU

# Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs  
and Drug Control

MUSCAT

Circular No. 149/ 2020

30 -12-1441 H

20 -08-2020



سِلاطِنَاةُ عُومَانِ  
وَزَارَةُ الصِّحَّةِ  
وَالرِّقَابَةِ الدُّوَالِيَّةِ  
مَسْقَط

## Half Yearly Report of Pharmacovigilance (January – June 2020)

Please find the half yearly report of **Pharmacovigilance in Oman** (reported for **January to June 2020**) which is uploaded in the e-portal, under “Periodical Reports” - <https://www.moh.gov.om/en/web/dgpadc/-7>.

The report is self-explanatory and we thank all the reporters for sending their reports during this period.

The healthcare professionals are kindly requested to report any adverse events or side effects associated with the use of any medicinal product to the Department of Pharmacovigilance & Drug Information in DGPA&DC.

  
**Dr. Mohammed Hamdan Al Rubaie**  
**DIRECTOR GENERAL**





Sultanate of Oman  
Ministry of Health  
Directorate General of Pharmaceutical Affairs & Drug Control  
*Department of Pharmacovigilance & Drug Information*

# HALF-YEARLY PV REPORT

## January – June 2020



## Table of Contents

Introduction	3
Adverse Drug Reactions Reports	4
Quality Problems reports	8
Medication Errors Reports	9

## 1. Introduction

The Department of Pharmacovigilance & Drug Information (DPV&DI), which is the National PV Center (NPVC), after implementation of VigiFlow (VF), has been able to activate (**212**) VigiFlow user accounts in their respective names linked to their emails, under the different regional (**34 Centres**) and sub-regional (**80 Centres**) pharmacovigilance centres (**Fig.1**). Awareness workshops conducted in Muscat governorate Headquarters, North and South Sharqiyah headquarters, and Al Masarrah hospital facilitated many Pharmacists and Asst. Pharmacists, doctors and nurses to get hands on training on how to manage ADR reporting through the VigiFlow. The cooperation extended by the PV focal points is commendable in spreading the message across the country.

The e- Reporting process implemented by the DGPA&DC has attracted attention of private sector Pharmacists and public alike. The patients, health care professionals from private sector are encouraged to report to Pharmacovigilance department through e-Reporting <https://www.moh.gov.om/en/ereporting-pharmacovigilance-department>


The focal points/ individual reporters are encouraged to contact the department for any clarifications or any assistance regarding reporting of adverse drug reactions or quality problems/ Medication errors. The DPV&DI can arrange zoom meetings if required for any sort of training required for VigiFlow entry.

### Boxed Warning:

#### *Note to all Manufacturing Authorization holders:*

Kindly refrain from re - sending the ICSRs listed in this half yearly report again to the DPV&DI channels as it will cause duplication in the reports.

**Figure (1): Structure of VigiFlow users**





## 2. ADR Reports:

The total number of ADR reports received and entered in the national database (VigiFlow) between January and June 2020 was (722), name of institutions and the numbers of reports are given in **Table (1)**. There were (9) reports, which were submitted manually and not yet processed in the VigiFlow, name of institutions and the numbers of reports are given in **Table (2)**.

From the reporting rate as shown, Table 1, the **highest reporting hospital** is *Sultan Qaboos University Hospital (SQUH)* [Total ADR reports 190] followed by *Nizwa Hospital* [Total ADR reports 74]. The **governorate with the highest number of reports** is *North Sharqiyah*, with (202) reports. Among the **private institutions**, *Kims Oman hospital /Pharmacy* is the highest with (14) reports.

The patient sex distribution, the age group distribution of patients, the top ten reported drugs, and frequently reported suspected reactions, are depicted as graphs in Fig. 2, 3, 4, and 5 respectively.

The **highest reported drug** is *Lisinopril* while the **highest reported reaction** is *Gastrointestinal disturbances including gastritis, GI upset, etc.,*. The reactions classified by System – Organ Classification (SOC), gastrointestinal disorders ranked the followed by Skin and subcutaneous system disorders. Top reported drug classes are alimentary tract and metabolism including the antidiabetic drugs followed by blood and blood forming organs. For the list of drugs-reactions, refer to Table (6)

**Table (1): ADR Reports that are processed in VigiFlow**


Region	Institution	No. of reports
<b>Dakhilia (76)</b>	Nizwa Hospital	74
	Bahla Hospital	1
	Firq HC	1
<b>Dhahira (27)</b>	Ibri EHC	17
	Hajar HC	3
	Tanam HC	2
	Ibri Hospital	2
	Akhdar HC	2
	Ainin HC	1
<b>Dhofar (34)</b>	Sultan Qaboos Hospital	34
<b>Buraimi (1)</b>	Mahdhah HC	1
<b>Muscat Tertiary Hospitals</b>	Royal Hospital	9
<b>Muscat (MOH facilities) (23)</b>	Massarah Hospital	12
	Mawalleh HC	5
	Al Khoud HC	2
	Qurayat EHC	1
	North Alkhwair HC	1
	Wattayyah HC	1

	Seeb HC	1
<b>Batinah North (3)</b>	Sohar Hospital	3
<b>Sharqiyah North (202)</b>	Ibra EHC	60
	Bidiya Hospital	50
	Al Qabil HC	27
	Wadi Andam HC	13
	Sinaw Hospital	11
	Mudhaybi HC	9
	Wadi Tayyin Hospital	8
	Miss HC	7
	Wadi Bani Khalid Hospital	5
	Wadi Dama HC	4
	Wadi Naam HC	2
	Ismayya HC	2
	Al Ayun HC	2
	Samad HOspial	1
	Dhahir HC	1
<b>Sharqiyah South (21)</b>	Sur Hospital	8
	Specialist Sur Diabetic Center	6
	JBB Ali Hospital	6
	Ras Al Hadd HC	1
<b>Sultan Qaboos University Hospital</b>		190
<b>Armed Force Hospital</b>		6
<b>ROP Hospital</b>		8
<b>Private (91)</b>		
<b>Private Pharmacies/Hospital/Clinics</b>	Kims Hospital	14
	Badr Al Sama Pharmacy	4
	Muscat Pharmacy	3
	Star Care Oman	3
	Azhar Private Hospital	1
	Taiba Health care	2
<b>Pharmaceutical Companies</b>	Merck	33
	Novartis	15
	Roche	7
	Astra Zeneca	5
	Remedica	1
	Lilly	1
	Hikma	1
	Amgen	1
<b>Patient (e Reporting)</b>		2
<b>Vaccines (AEFI) (Dept. of Communicable diseases)</b>		16
<b>Blanks</b>		13
<b>Grand Total</b>		<b>722</b>


**Table (2) ADR Reports that are not processed in VigiFlow**

Institutions/Governorate	Reports no.
<b>Musandam (6)</b>	
Dibba Hospital	4
Lima Health Centre	2
<b>North Sharqiyah (1)</b>	
Mudaibi Health Centre	1
<b>South Batinah (1)</b>	
Barka PC	1
<b>Private Institutions</b>	
Al Raffah Hospital Pharmacy	1
<b>Total</b>	<b>9</b>

**Figure (2): Patient – Sex Distribution**




**Figure (3): Patient Age Group Distributions**






**Figure (4): Top Ten Suspected Drugs**



**Figure (5): Frequently Occurring Reactions**



**Note:**

Please note that Figure 2 to Figure 5 and Table 6, refer to the ADR reports that are processed in the VigiFlow.

### 3. Quality Problems Reports (QPR)

There were (31) product quality reports received at the DPV&DI from government institutions, and private sector, (Table 3). Table (4) shows the reported quality problems according to dosage forms.

Table (3): QPR (Received through VF)

Sr	Institution	Governorate	No. of QPRs
<b>Ministry of Health</b>			
1	Mawalleh HC	Muscat	2
2	Wattayyah HC	Muscat	2
3	North Al Khwair HC	Muscat	3
4	Al Khoud HC	Muscat	2
5	Royal Hospital	Muscat	1
6	Nizwa Hospital	Dakhliya	3
7	Ibra EHC	Sharqiyah North	7
8	Miss HC	Sharqiyah North	4
9	Rustaq Hospital	Batinah South	2
<b>Public Health Institutions</b>			
10	Royal Oman Police Hospital	Muscat	2
<b>Private sector</b>			
11	Muscat Pharmacy		1
12	Novartis		2
13	Sanofi		1
	<b>Total</b>		<b>31</b>

Table (4): Reported Quality Problems according to dosage forms

Dosage Form	Reported Quality Problem
<b>Parenteral dosage forms</b>	
	Empty ampoule in the original packing.
	Ampoules without label
<b>Oral dosage forms</b>	
	Missing tablet in sealed strips
	Damaged / broken Tab. / inside the sealed strips
	One tablet found dissolved in the sealed strip
	Tablet coating issue- chipped coating
	Shrunk tablets like exposed to heat in sealed strip
	Leakage of powder from capsule in sealed strips
	Patient / Not Tolerated / Ineffectiveness

	Patient complaint due to change of brand/ ineffectiveness.
	Caking of powder/ granules in sachet
	Swollen sachet
	Look alike medications – similar packs with outer label
<b>Respiratory (inhaled) dosage forms</b>	
	Product ineffectiveness
<b>Topical Dosage Forms</b>	
	Product Ineffectiveness

#### 4. Medication Errors Reports (MER)

The DPV&DI received (54) Medication Error reports in this half year (Table 5). P method was done to determine the type of errors.

**Table (5) Medication Error Reports:**

Sr.No.	ME type	No. of reports
1	Prescribing errors	51
2	Administration error	1
3	Dispensing error	1
4	Wrong dose (due to leakage of insulin)	1
	<b>Total</b>	<b>54</b>

**Table (6): List of Drug- Reactions July to December 2019**

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
1	2 Month	Female	Acetylsalicylic acid	Pain chest
2	63 Year	Male	Aciclovir	Acute kidney injury
3	21 Year	Female	Aciclovir	Abscess
4	21 Year	Female	Aciclovir	Crystal nephropathy
5	37 Year	Female	Adalimumab	Colitis
6	25 Year	Male	Adalimumab	Pain
7	65 Year	Male	Adalimumab	Psoriasis flare-up
8	38 Year	Female	Agalsidase beta	Erythematous rash
9	39 Year	Male	Allopurinol, Diclofenac	Stevens Johnson reaction
10	49 Year	Female	Alpelisib	Diabetic ketoacidosis
11	49 Year	Female	Alpelisib	Edema
12	33 Year	Female	amino acid L-cystine and calcium pantothenate	Diarrhea
13	68 Year	Male	Aminophylline	Supraventricular tachycardia
14	42 Year	Male	Amiodarone	Hepatotoxicity
15	48 Year	Male	Amitripylline	Hyperacidity
16	51 Year	Female	Amlodipine	Dysphonia
17	90 Year	Male	Amlodipine	Edema legs
18	61 Year	Female	Amlodipine	Gastritis
19	60 Year	Female	Amlodipine	Oedematous feet
20	56 Year	Female	Amlodipine	Headache
21	57 Year	Female	Amlodipine	Puffy skin
22	99 Year	Female	Amlodipine	Dry cough
23	56 Year	Female	Amlodipine	Heartburn
24	68 Year	Female	Amlodipine	Leg edema
25	67 Year	Female	Amlodipine	Edema
26	79 Year	Female	Amlodipine	Pedal edema
27	77 Year	Female	Amlodipine	Edema lower limb
28	58 Year	Female	Amlodipine	Leg edema
29	55 Year	Female	Amlodipine	Tongue dry
30	55 Year	Female	Amlodipine	Fatigue
31	NA	Female	Amlodipine/Valsartan	Hyponatremia
32	9 Month	Male	Amoxicillin	Rash

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
33	18 Year	Male	Amoxicillin	Allergy
34	4 Year	Male	Amoxicillin	Skin rash
35	NA	Male	Amoxicillin	Drug allergy
36	5 Year	Male	Amoxicillin	Diarrhea
37	42 Year	Male	Amoxicillin	Heartburn
38	1 Year	Male	Amoxicillin	Diarrhea
39	7 Year	Male	Amoxicillin	Allergy
40	1 Year	Male	Amoxicillin	Erythromacular rash
41	60 Year	Female	Amoxicillin	Allergy
42	1 Year	Male	Amoxicillin	Allergy
43	4 Year	Male	Amoxicillin	Diarrhea
44	28 Year	Male	Amoxicillin	Loose stools
45	37 Year	Male	Amoxicillin/Clavulanic acid	Allergy
46	3 Year	Male	Amoxicillin/Clavulanic acid	Vomiting
47	4 Year	Male	Amoxicillin/Clavulanic acid	Allergic reaction
48	NA	Female	Amoxicillin/Clavulanic acid	Allergy
49	NA	Male	Amoxicillin/Clavulanic acid	Drug allergy
50	24 Year	Female	Amoxicillin/Clavulanic acid	Pain
51	NA	Female	Amoxicillin/Clavulanic acid	Skin rash
52	38 Year	Female	Amoxicillin/Clavulanic acid	Allergy
53	2 Year	Male	Amoxicillin	Rash
54	33 Year	Female	Amoxicillin/Clavulanic acid ,Metronidazole	Allergy
55	28 Year	Male	Amphotericin B	Hypokalemia
56	66 Year	Female	Amphotericin B	Watery diarrhea, Hypotension, Oxygen saturation decreased, Vomiting
57	28 Year	Unknown	Amphotericin B	Hypokalemia
58	68 Year	Female	Ampicillin	Urticaria
59	46 Year	Male	Ampicillin	Nephritis interstitial
60	NA	Male	Analgesic patch	Application site edema
61	NA	Female	Anidulafungin	Dizziness
62	31 Year	Male	Antithymocyte immunoglobulin	Fever
63	62 Year	Male	Aprepitant	Hiccups

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
64	63 Year	NA	Artificial tears	Burning sensation in eye
65	64 Year	Female	Artificial tears	Blurred vision
66	NA	Female	Artificial tears	Eye redness
67	60 Year	Male	Acetylsalicylic Acid	Hyperacidity
68	82 Year	Female	Acetylsalicylic Acid	Flatulence
69	69 Year	Male	Acetylsalicylic Acid	Sedation
70	60 Year	Male	Acetylsalicylic Acid	Eye dryness, Dry throat
71	64 Year	Female	Acetylsalicylic Acid	GI upset
72	42 Year	Female	Acetylsalicylic Acid, Folic acid, Chlorpheniramine maleate	Allergy
73	78 Year	Female	Acetylsalicylic Acid	Blurred vision
74	60 Year	Female	Atenolol	Persistent dry cough
75	47 Year	Male	Atorvastatin	Fatigue
76	82 Year	Female	Atorvastatin	Myalgia
77	60 Year	Female	Atorvastatin	Heartburn
78	59 Year	Male	Atorvastatin	Muscle pain
79	60 Year	Female	Atorvastatin	Allergy
80	66 Year	Female	Atorvastatin	Heartburn
81	65 Year	Female	Atorvastatin	Dizziness
82	41 Year	Female	Atorvastatin	Urea urine
83	42 Year	Male	Atorvastatin	Myalgia
84	60 Year	Male	Atorvastatin	Diarrhea
85	71 Year	Female	Atorvastatin	Cough
86	55 Year	Female	Atorvastatin	Dyspepsia
87	73 Year	Female	Atorvastatin	Gastritis
88	72 Year	Female	Atorvastatin	Gastritis
89	73 Year	Male	Atorvastatin	Dry mouth
90	66 Year	Male	Atorvastatin	Erectile dysfunction
91	77 Year	Female	Atorvastatin	Leg pain
92	NA	Female	Atorvastatin, Amlodipine, Acetylsalicylic Acid, Furosemide, Atenolol	Tremor
93	NA	Male	Atorvastatin, Amlodipine, Atenolol	Tremor
94	NA	Female	Atorvastatin, Atenolol, Amlodipine	Tremor
95	57 Year	Female	Atorvastatin	Cough
96	53 Year	Female	Atorvastatin	Myositis



SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
97	59 Year	NA	Atorvastatin	Rebound hyperacidity
98	56 Year	Female	Atorvastatin	Epigastric pain
99	62 Year	Female	Atorvastatin	Myopathy
100	1 Month	Male	Atorvastatin	Dizziness
101	70 Year	Male	Atorvastatin	Muscle pain
102	53 Year	Female	Atorvastatin	Rash
103	67 Year	Female	Atorvastatin	Oedema
104	67 Year	Female	Atorvastatin	Cough
105	67 Year	Female	Atorvastatin	Oedema arms
106	54 Year	Female	Azacitidine	Marrow hypercellular
107	60 Year	NA	Bacillus Clausii	Rash,Itching both hands
108	69 Year	Male	Baclofen	Convulsion,CNS depression
109	NA	Female	BCG Vaccine	Injection site abscess
110	2 Month	Female	BCG Vaccine	Vaccination site swelling
111	12 Month	Female	BCG Vaccine	Septic joint
112	29 Year	Female	Bemiparin, Pantoprazole	Rash maculo-papular,Itching
113	31 Year	Male	Bisoprolol	Dry cough
114	23 Year	Male	Bisoprolol	Fatigue
115	64 Year	Female	Bisoprolol	Shortness of breath
116	29 Year	Female	Bisoprolol	Dizziness
117	34 Year	Female	Bleomycin	Productive cough
118	22 Year	Female	Bleomycin	Non-cystic fibrosis bronchiectasis
119	53 Year	Male	Brentuximab	Febrile neutropenia
120	31 Year	Female	Bromocriptine	Dizziness
121	50 Year	Female	Bromocriptine	Swelling face
122	70 Year	Female	Calcium with D3	Gastritis
123	NA	Male	Candesartan	Hyponatremia
124	44 Year	Male	Capecitabine	Lip discoloration
125	65 Year	Female	Captopril	Allergy
126	38 Year	Male	Carbamazepine	Toxicoderma
127	25 Year	Female	Carbamazepine	Dizziness
128	NA	Female	Carbamazepine	Hypertension
129	44 Year	Female	Carbimazole	Itching
130	60 Year	Female	Carboplatin	Palpitation,Vomiting,Low pulse rate

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
131	43 Decade	Female	Carboplatin	Low platelets
132	50 Year	Female	Carboplatin	Neutropenia
133	8 Year	Male	Carboplatin, Cyclophosphamide, Vincristin	Immune thrombocytopenia
134	40 Year	Female	Carboplatin, Gemcitabine	Low platelets
135	68 Year	Female	Carfilzomib	Hypertension
136	43 Year	Male	Caspofungin	Nausea
137	2 Month	Female	Cefalexin	Tremor
138	8 Year	Female	Cefalexin	Allergic skin reaction
139	30 Year	Male	Cefazolin	Rash NOS
140	25 Year	Male	Cefazolin	Rash
141	33 Year	Female	Cefazolin	Allergic rash
142	NA	Male	Cefepime	Breathing difficult, Rash Vomiting
143	NA	Male	Cefepime	Itching, Redness
144	38 Year	Male	Cefixime	Allergy
145	39 Year	Female	Ceftazidime	Rash
146	39 Year	Female	Ceftazidime	Rash
147	NA	Female	Ceftriaxone	Sweating
148	72 Year	Female	Ceftriaxone	Itching
149	NA	Female	Ceftriaxone	Itching
150	17 Year	Female	Ceftriaxone	Anaphylaxis
151	21 Year	Male	Ceftriaxone	Anaphylactic shock
152	11 Year	Male	Ceftriaxone	Itchy rash, Abdominal pain, Chest pain, Shortness of breath, Diarrhea
153	27 Year	Male	Ceftriaxone, Ciprofloxacin	Allergic reaction
154	76 Year	Female	Cefuroxime	Diarrhea
155	5 Month	Male	Cefuroxime	Acute diarrhoea
156	NA	Male	Celecoxib	Penile erythema, Oral mucosa swollen, Bullous eruption
157	2 Year	Male	Cephalexin	Diarrhea
158	53 Year	Male	Cetuximab	Itching all over
159	44 Year	Female	Chlorpheniramine	Palpitation
160	5 Year	Female	Chlorpheniramine	Sedation

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
161	31 Year	Male	Chlorpheniramine	Allergy
162	25 Year	Female	Chlorpheniramine	Headache
163	62 Year	Female	Chlorpheniramine	Dizziness
164	10 Year	Male	Chlorpheniramine	Dizziness
165	NA	Male	Chlorpheniramine	Hyperactivity
166	70 Year	Male	Chlorpromazine	Neuroleptic malignant syndrome, Hyperthermia malignant
167	37 Year	Male	Ciprofloxacin	Tonsillitis
168	NA	Female	Ciprofloxacin	Erythema
169	NA	Female	Ciprofloxacin	Acidity
170	73 Year	Male	Cisplatin	Low platelets
171	72 Year	Male	Cisplatin Etoposide	Herpes simplex meningoencephalitis, Fever, Somnolence, Seizure, Coma Stroke, Thrombocytopenia Lymphopenia
172	26 Year	Male	Citalopram	Sleepy
173	25 Year	Female	Clarithromycin	Vomiting
174	NA	Male	Clarithromycin	Taste altered, Epigastric pain
175	62 Year	Male	Clarithromycin	Nausea
176	5 Year	Female	Clobazam	Sedation
177	11 Year	Female	Clobazam	Eyes swollen
178	33 Year	Male	Clonazepam	Convulsion
179	66 Year	Female	Clopidogrel	Platelet count decreased
180	53 Year	Male	Clopidogrel	Allergy
181	38 Year	Male	Cloxacillin	Heartburn
182	36 Year	Male	Co-trimoxazole	Pancytopenia
183	57 Year	Male	Colistin	Acute kidney injury
184	NA	Unknown	Colistin	Acute kidney injury
185	64 Year	Male	Contrast media	Acute renal failure
186	5 Year	Female	Co-trimoxazole	LFTs raised
187	3 Year	Male	Co-trimoxazole	Hoarseness of voice
188	13 Year	Female	Co-trimoxazole	Raised LFTs
189	13 Year	Female	Crizanlizumab	Bacterial meningitis, Brain herniation Septic shock, Brain edema

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
190	3 Year	Female	Cyclizine	Hallucination
191	14 Month	Female	Cyclopentolate/Phenylephrine	Fever, Redness facial
192	63 Year	Male	Cyclophosphamide	Neutropenia
193	43 Year	Female	Cyclophosphamide	Urinary incontinence
194	50 Year	Male	Cyclophosphamide	Febrile neutropenia
195	57 Year	Male	Cyclosporine, Mycophenolate mofetil, Methylprednisolone, Prednisolone	BK virus nephropathy, Cytomegalovirus infection, Kidney function abnormal
196	21 Year	Female	Cytarabine	Nausea
197	44 Year	Female	Cytarabine	Neutropenia
198	21 Year	Female	Cytarabine	Acute kidney injury
199	17 Year	Female	Cytarabine	Abdominal pain
200	43 Year	Female	Cytarabine	Mucositis
201	56 Year	Female	Cytarabine	Myelosuppression
202	21 Year	Female	Cytarabine	Anal fissure
203	56 Year	Female	Cytarabine	Pancytopenia
204	6 Year	Male	Cytarabine	Photophobia
205	3 Year	Female	Deferasirox	Bacterial infection
206	NA	NA	Deferasirox	Renal tubular acidosis
207	NA	Female	Deferasirox	Throat pain
208	13 Year	Female	Deferasirox	Hypothyroidism, Hyperpigmentation skin
209	17 Year	Female	Deferasirox, Hydroxyurea	Fainting, Hypotensive
210	NA	NA	Deferiprone	Elevated liver enzymes
211	32 Year	Female	Deferiprone	Febrile neutropenia
212	30 Year	Female	Deferiprone	Hematuria
213	36 Year	Male	Dexamethasone	Hiccup
214	12 Year	Male	Dexamethasone	Weight gain
215	62 Year	Female	Dexamethasone	Hyperglycemia
216	64 Year	Male	Dexamethasone	Hyperglycemia
217	16 Year	Male	Dexamethasone	Blood glucose increased
218	62 Year	Female	Dexamethasone	Blood sugar increased
219	NA	Female	Dexketoprofen	Itching
220	25 Year	Male	Diclofenac	Acidosis
221	22 Year	Male	Diclofenac	Itching
222	49 Year	Female	Diclofenac	Hypotension

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
223	51 Year	Female	Diclofenac	Gastritis
224	NA	Male	Diclofenac	Periorbital edema
225	77 Year	Female	Diclofenac	Allergy
226	48 Year	Male	Diclofenac	Skin rash
227	35 Year	Male	Diclofenac	Redness
228	NA	Male	Diclofenac	Rash, Skin eruption
229	21 Year	Male	Diclofenac	Acute kidney injury
230	62 Year	Female	Diclofenac	Hydronephrosis
231	62 Year	Female	Diclofenac	Hydronephrosis
232	33 Year	Male	Diclofenac	Eye redness
233	18 Year	Female	Diclofenac	Vomiting, Nausea, Acute kidney injury
234	78 Year	Female	Diclofenac ,Acetylsalicylic acid	Angioedema
235	40 Year	Female	Dietary supplement	Nausea, Insomnia, Discomfort
236	NA	Female	Docetaxel	Allergic reaction
237	30 Year	Female	Docetaxel	Fluid retention
238	39 Year	Female	Doxorubicin	Febrile neutropenia
239	44 Year	Female	Doxorubicin	Mucositis
240	37 Year	Female	Doxorubicin	Febrile neutropenia
241	18 Month	Male	DPT Vaccine	Swelling
242	18 Month	Female	DPT Vaccine	Convulsions
243	18 Month	Male	DPT Vaccine	Swelling
244	18 Month	Male	DPT Vaccine	Administration site swelling
245	NA	Female	Drospirenone, Ethinylestradiol	Deep vein thrombosis leg
246	6 Year	Male	DT vaccine	Fever
247	6 Year	Male	DT vaccine	Swelling
248	2.3 Year	Male	DTPa-hepB-IPV-Hib vaccine	Urticarial rash
249	45 Year	Male	Durvalumab	Disease progression NOS
250	45 Year	Male	Efavirenz/Emtricitabine/Tenofovir	Neuropsychiatric symptoms
251	NA	Unknown	Eltrombopag	Elevated liver enzymes
252	65 Year	Male	Enoxaparin, phenytoin	Heparin-induced thrombocytopenia
253	27 Year	Female	Enoxaprin	Melena
254	58 Year	Female	Entecavir	Dry cough
255	34 Year	Female	Erythromycin	Vomiting

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
256	45 Year	Female	Erythromycin	Gastritis
257	47 Year	Female	Erythromycin	Diarrhea
258	9 Year	Male	Erythromycin	Pain during injection
259	58 Year	Male	Esomeprazole	Hypomagnesemia
260	21 Year	Female	Esomeprazole	Acute kidney injury
261	62 Year	Male	Esomeprazole	Nephritis interstitial
262	49 Year	Male	Esomeprazole	Pruritic rash
263	74 Year	Male	Ethambutol	Hepatotoxicity
264	74 Year	Male	Ethambutol	Hepatotoxicity
265	65 Year	Female	Ethylchloride	Allergic skin reaction Skin burning sensation
266	36 Year	Female	Ethylchloride	Allergic skin reaction Burning skin
267	19 Year	Female	Ethylchloride	Allergic skin reaction
268	44 Year	Female	Ethylchloride	Allergic skin reaction
269	NA	Female	Etonogestrel	Hypersensitivity, Rash
270	NA	Female	Etoricoxib	Lip swelling, Genital itching
271	NA	Female	Etoricoxib	Edema lip, Tingling lips
272	40 Year	Female	Everolimus	Hemolysis
273	NA	Female	Evolocumab, Rosuvastatin	Rash lips, Lip swelling
274	77 Year	Female	Felodipine	Dizziness
275	55 Year	Female	Fentanyl	Vomiting, Dizziness, Fatigue
276	65 Year	Female	Fentanyl	Vomiting, Nausea
277	24 Year	Female	Ferrous sulfate	Nausea
278	34 Year	Female	Ferrous sulfate	Constipation
279	28 Year	Female	Ferrous sulfate/Folic acid	Vomiting
280	30 Year	Female	Ferrous sulfate/Folic acid	Vomiting
281	31 Year	Female	Ferrous Sulfate/Folic Acid	Constipation
282	42 Year	Female	Ferrous Sulfate/VitC/Folic Acid	Skin dry
283	25 Year	Female	Ferrous sulphate	Acute diarrhea
284	40 Year	Female	ferrous sulphate	Heartburn
285	32 Year	Female	Ferrous sulphate	Palpitation
286	51 Year	Female	Ferrous sulphate	Constipation
287	25 Year	Female	Ferrous sulphate	Constipation



SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
288	47 Year	Female	Ferrous sulphate	Gastritis
289	30 Year	Female	Ferrous sulphate	Gastritis
290	34 Year	Female	Ferrous sulphate	Constipation
291	28 Year	Female	Ferrous sulphate/ folic acid	Constipation
292	21 Year	Female	Ferrous sulphate/ folic acid	Gastritis
293	21 Year	Female	Ferrous sulphate/Folic acid	Epigastric pain
294	38 Year	Female	Ferrous sulphate/Folic acid	Epigastric pain
295	30 Year	Female	Ferrous sulphate/folic acid	Vomiting
296	27 Year	Female	Ferrous sulphate/folic acid	Constipation
297	36 Year	Female	Ferrous sulphate/folic acid	Vomiting
298	24 Year	Female	Ferrous sulphate	Epigastric pain
299	44 Year	Female	fexofenadine, Mometasone	Micturition burning
300	52 Year	Female	Flucloxacillin	Vomiting
301	63 Year	Female	Flucloxacillin	Burning sensation Swelling
302	39 Year	Male	Flunarizine	Gastrointestinal upset
303	29 Year	Male	Fluoxetine	Blurred vision
304	16 Year	Female	Fluoxetine	Weight gain
305	41 Year	Female	Fluoxetine	Nausea
306	61 Year	Male	Fluticanose	Sore throat
307	35 Year	Male	Folic acid	Gastritis
308	42 Year	Female	Folic acid	Constipation
309	47 Year	Female	Folic acid	Hyperacidity
310	55 Year	Male	Fucidic acid	Allergy
311	80 Year	Female	Furosemide	Fatigue
312	92 Year	Female	Furosemide	Frequency urinary
313	23 Day	Female	Furosemide/Hydrochlorithiazide	Neonatal hyponatremia
314	51 Year	Female	Gabapentin	Hallucination
315	60 Year	Male	Gadoteric acid	Skin rash
316	NA	Female	Gadoteric acid	Skin rash
317	45 Year	Female	Gefitinib	Disease progression NOS
318	51 Year	Female	Gemcitabine	Thrombocytopenia
319	66 Year	NA	Gemcitabine	Thrombocytopenia
320	48 Year	Female	Gemcitabine	Thrombocytopenia
321	63 Year	Female	Gliclazide	Hypoglycemia

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
322	80 Year	Male	Gliclazide, metformin	Severe hypoglycemia
323	80 Year	Female	Glyceryl trinitrat	Mouth ulcer
324	79 Year	Female	Glyceryl trinitrate	Tremor
325	NA	Female	Granisetron	Rash erythematous
326	NA	Female	Haloperidol	Abdominal cramp
327	NA	Female	Hand sanitizer	Allergic skin reaction
328	80 Year	Male	Heparin	Heparin-induced thrombocytopenia
329	56 Year	Female	Hepatitis B vaccine	Weakness generalized
330	56 Year	Male	Hepatitis b vaccine	Weakness generalized, Nausea
331	42 Year	Male	Hydrochlorothiazide	Heart rate irregular
332	67 Year	Female	Hydrochlorothiazide	Cough
333	88 Year	Female	Hydrochlorothiazide	Cough
334	60 Year	Female	Hydrochlorothiazide	Sodium low
335	62 Year	Female	Hydrochlorothiazide	Acidosis
336	69 Year	Male	Hydrocortisone	Tachycardia Hyperglycemia
337	68 Year	Female	Hydrocortisone	Fever
338	64 Year	Male	Hydrocortisone	Flushing
339	NA	Female	Hydrocortisone	Drug allergy
340	NA	Male	Hydrocortisone	Flushing in head
341	71 Year	Male	Hydrocortisone	Nausea, Vomiting
342	54 Year	Male	Hydroxycarbamide	Low platelets
343	67 Year	Female	Hydroxychloroquine	Electrocardiogram QTc interval borderline prolonged
344	34 Year	Female	Hydroxychloroquine	Epigastric pain
345	29 Year	Male	Hydroxychloroquine, Lopinavir/ritonavir	Electrocardiogram QTc interval prolonged Watery diarrhea
346	50 Year	Male	Hydroxychloroquine, Lopinavir/ritonavir	Electrocardiogram QTc interval prolonged
347	51 Year	Male	Hydroxychloroquine, Azithromycin, Lopinavir/Ritonavir	QT prolonged
348	21 Year	Female	Hydroxyurea	Dizziness
349	57 Year	Male	Hydroxyurea	Gastritis
350	11 Year	Male	Hydroxyurea	Bone marrow toxicity

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
351	59 Year	Male	Hyoscine	Dry mouth
352	NA	Male	Ibuprofen	Palpitations
353	13 Year	Male	Ibuprofen	Hyperacidity
354	32 Year	Female	Ibuprofen	Heartburn
355	NA	Female	Ibuprofen	Swallowing difficult
356	63 Year	Female	Ibuprofen	Gastritis
357	NA	Female	Ibuprofen	Poisoning by acidifying agents
358	14 Year	Male	Ibuprofen	Acidosis
359	37 Year	Male	Ibuprofen	Acidosis
360	34 Year	Female	Ibuprofen	Heartburn
361	48 Year	Male	Ibuprofen	Gastritis
362	33 Year	Female	Ibuprofen	Gastritis
363	45 Year	Female	Ibuprofen	Kidney pain
364	23 Year	Female	Ibuprofen	Gastritis
365	56 Year	Female	Ibuprofen	Gastritis
366	23 Year	Male	Ibuprofen	Allergy
367	NA	Male	Ibuprofen	Rash ,Shortness of breath, Flushing of face
368	21 Year	Male	Ibuprofen	Allergy
369	36 Year	Male	Ibuprofen	Allergy
370	NA	Female	Ibuprofen	Sensitive skin
371	NA	Female	Ibuprofen	Dysmenorrhea
372	41 Year	Female	Ibuprofen	Fatigue
373	42 Year	Male	Ibuprofen	Heartburn
374	9 Year	Male	Ibuprofen	Allergy
375	NA	Male	Ibuprofen	Itching
376	50 Year	Male	Ibuprofen	Itching
377	25 Year	Male	Ibuprofen	Shortness of breath
378	40 Year	Male	Ibuprofen	Allergy
379	28 Year	Male	Ibuprofen	Drug-induced asthma
380	16 Year	Female	Inotuzumab	Abdominal pain
381	25 Year	Female	Inotuzumab/Ozogamicin	Alanine aminotransferase increase
382	NA	Unknown	Insulin	Shivering
383	35 Year	Female	Insulin regular	Allergy

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
384	NA	Male	Interferon beta	Flu like symptoms
385	NA	Male	Interferon beta	Fever
386	NA	Female	Interferon beta	Maternal exposure during pregnancy, first trimester
387	NA	Male	Interferon beta	Injection site induration
388	NA	Female	Interferon beta	Maternal exposure during pregnancy, first trimester
389	NA	Female	Interferon beta	Shoulder pain, Weakness
390	NA	Female	Interferon beta	Low back pain
391	NA	Female	Interferon beta-1a	Bruising of thigh, Redness of legs
392	NA	Female	Interferon beta-1a	Low back pain, Neck pain
393	NA	Female	Iohexol	Generalized itching, Erythematous rash Stomach pain
394	1 Year	Male	Irbesartan	Dizziness
395	38 Year	Female	Irinotecan	Extravasation
396	52 Year	Male	Irinotecan	Numbness in feet
397	45 Year	Female	Irinotecan	Deranged liver function tests
398	74 Year	Male	Isoniazid	Hepatotoxicity
399	68 Year	Female	Isosorbide dinitrate	Headache
400	66 Year	Female	Isosorbide dinitrate	Headache
401	NA	Female	Isosorbide Mononitrate	Dizziness
402	66 Year	Male	Isosorbide Mononitrate, Furosemide, Carvedilol Valsartan, Spironolactone	Hypotension
403	9 Year	Female	Ivacaftor	Fatty liver
404	12 Year	Male	Ivacaftor	Fatty liver
405	26 Year	Female	Labetalol	Angioedema
406	54 Year	Female	Labetalol	Shortness of breath
407	50 Year	Female	Labetalol	Abdominal cramp
408	28 Year	Female	Lacosamide	Musculoskeletal pain
409	47 Year	Female	Lamotrigine	Numbness
410	NA	Female	Lansoprazole, Diclofenac,	Rash
411	NA	NA	Latanoprost	Raised IOP
412	47 Year	Female	Latanoprost	Sensation of pressure in eye
413	52 Year	Male	Latanoprost	Eye irritation, Eye redness

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
414	60 Year	Male	Latanoprost	Eye irritation, Eye redness
415	60 Year	Male	Latanoprost	Eye irritation, Eye redness
416	67 Year	Female	Latanoprost	Anterior uveitis
417	44 Year	Female	Lenalidomide	Swelling
418	52 Year	Female	Lenalidomide	Allergic reaction
419	57 Year	Female	Lenalidomide	Hypotension
420	41 Year	Male	Lenalidomide	Autonomic dysfunction
421	59 Year	NA	Lenalidomide	Erythromacular rash
422	48 Year	Female	Letrozole, Exemestane, Fulvestrant, Everolimus, Capecitabine	Allergy
423	24 Year	Female	Levetiracetam	Dizziness
424	28	Female	Levetiracetam	Depression
425	32 Year	Male	Levetiracetam, Amlodipine, Calcium & D3 Vit	Headache
426	12 Year	Female	Levetiracetam, Carbamazepine	Aggressiveness
427	NA	Male	Levofloxacin	Itching Skin rash
428	NA	Male	Levofloxacin	Rash
429	NA	Female	Levofloxacin	Itching
430	43 Year	Male	Levopubivacaine	Seizure, Cardiac arrest Oxygen saturation decreased, Hypotension
431	63 Year	Female	Levothyroxine	Tachycardia
432	36 Year	Female	levo-thyroxine	Gastritis
433	23 Year	Male	Linezolid	Platelet count low
434	51 Year	Female	Lisinopril	Dry cough
435	NA	NA	Lisinopril	Cough
436	81 Year	Male	Lisinopril	Cough
437	54 Year	Female	Lisinopril	Cough
438	75 Year	Male	Lisinopril	Cough
439	83 Year	Male	Lisinopril	Giddiness
440	55 Year	Male	Lisinopril	Cough
441	55 Year	Female	Lisinopril	Cough
442	59 Year	Male	Lisinopril	Cough
443	61 Year	Male	Lisinopril	Dry cough
444	70 Year	Female	Lisinopril	Potassium high

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
445	67 Year	Female	Lisinopril	Dry cough
446	62 Year	Male	Lisinopril	Tongue edema
447	78 Year	Female	Lisinopril	Tongue edema
448	70 Year	Male	Lisinopril	Coughing
449	41 Year	Male	Lisinopril	Dry cough
450	76 Year	Male	Lisinopril	Dry cough
451	78 Year	Male	Lisinopril	Dizziness
452	76 Year	Female	Lisinopril	Retention water
453	62 Year	Female	Lisinopril	Coughing
454	57 Year	Female	Lisinopril	Coughing
455	57 Year	Female	Lisinopril	Cough
456	60 Year	Male	Lisinopril	Cough
457	68 Year	Female	Lisinopril	Chest pain
458	64 Year	Male	Lisinopril	Heart rate increased
459	60 Year	Male	Lisinopril	Cough
460	54 Year	Female	Lisinopril	Coughing
461	NA	Male	Lisinopril	Dry cough
462	67 Year	Female	Lisinopril	Dry cough
463	56 Year	Male	Lisinopril	Hyperkalemia
464	65 Year	Female	Lisinopril	Dryness oral
465	63 Year	Female	Lisinopril, Vancomycin, Amlodipine, Sitagliptin Co-trimoxazole	Lichen planus
466	48 Year	Male	lithium	Nausea
467	32 Year	Male	Lopinavir/ritonavir	Derangement of liver function tests
468	83 Year	Female	Lopinavir/ritonavir	Electrocardiogram QTc interval prolonged
469	45 Year	Male	Lopinavir/Ritonavir	GI upset
470	3 Day	Male	Lopinavir/Ritonavir	Abdominal symptom
471	99 Year	Male	Lopinavir/ritonavir, ,Clexane	Diarrhea, Hematuria
472	34 Year	Female	Loratadine	Lethargy, Dizziness
473	77 Year	Female	Low Molecular Weight Heparin, Ipratropium, Bromhexine	Deranged liver function tests
474	33 Year	Female	Magnesiumoxide	Diarrhea
475	59 Year	Female	Mefenamic acid	Back pain



SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
476	60 Year	Female	Mefenamic acid	Gastritis
477	76 Year	Male	Mefenamic acid	Gastritis
478	NA	Female	Mefenamic acid	Itching
479	37 Year	Male	Mefenamic acid	Gastrointestinal upset
480	NA	Female	Mefloquine	Vomiting
481	26 Year	Female	Mefenamic acid	Diarrhea
482	54 Year	Male	Meropenem	Chest pain
483	28 Year	Female	Metoclopramide	Acute dystonia
484	79 Year	Female	Metformin	Gastritis
485	39 Year	Female	Metformin	Gastritis
486	67 Year	Female	Metformin	Acidosis
487	65 Year	Female	Metformin	Itching
488	40 Year	Female	Metformin	General body pain, Gastrointestinal upset
489	50 Year	Female	Metformin	Appetite lost
490	36 Year	Male	Metformin	Diarrhea
491	NA	Female	Metformin	Gastric disorder
492	NA	Male	Metformin	Gastritis
493	48 Year	Male	Metformin	GI upset
494	64 Year	Male	Metformin	Hypoglycemia
495	19 Year	Female	Metformin	Vomiting
496	77 Year	Female	Metformin	Abdominal discomfort
497	NA	Male	Metformin	Gastritis
498	53 Year	Female	Metformin	GI upset
499	NA	Female	Metformin	Dyspepsia
500	50 Year	Male	Metformin	Myalgia
501	49 Year	Female	Metformin	Constipation
502	35 Year	Male	Metformin	Diarrhea
503	46 Year	Female	Metformin	Diarrhea
504	49 Year	Female	Metformin	Diarrhea
505	67 Year	Female	Metformin	Dehydration
506	33 Year	Female	Metformin	Diarrhea
507	73 Year	Male	Metformin	Diarrhea
508	NA	Male	Metformin	Allergy
509	65 Year	Female	Metformin	Gastric pain

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
510	31 Year	Female	Metformin	Diarrhea
511	85 Year	Female	Metformin	Epigastric pain
512	NA	Male	metformin/Sitagliptin	Epigastric pain Pancreatitis NOS
513	16 Year	Male	Methotrexate	Hypersensitivity
514	16 Year	Male	Methotrexate	Transaminitis
515	36 Year	Male	Methotrexate	Stools watery
516	44 Year	Female	Methotrexate	Neutropenia
517	16 Year	Female	Methotrexate	Diarrhea
518	36 Year	Male	Methotrexate	Transaminitis
519	NA	Male	Methotrexate, Prednisolone	Nausea
520	37 Year	Female	Methyldopa	Drug-induced liver injury
521	34 Year	Female	Methyldopa	Dry mouth
522	11 Year	Male	Methylphenidate	Decreased appetite
523	NA	Male	Methylphenidate, Risperidone	Tongue protrusion spastic involuntary
524	63 Year	Male	Methylprednisolone	Hyperglycemia
525	85 Year	Female	Metoclopramide	Allergy
526	31 Year	Male	Metoclopramide	Drug-induced extrapyramidal side effects
527	36 Year	Female	Metoclopramide, Dexamethasone Erythromycin	Allergy
528	43 Year	Female	Metronidazole	Dizziness
529	66 Year	Female	Metronidazole	Itching
530	6 Month	Female	Milrinone	Thrombocytopenia
531	50 Year	Female	Mirtazapine	Thrombocytopenia
532	40 Year	Female	Misoprostol	Diarrhea
533	40 Year	Female	Misoprostol	Diarrhoea
534	25 Year	Female	Misoprostol	Diarrhoea
535	23 Year	Female	Misoprostol	Diarrhea, Abdominal bloating
536	50 Year	Female	Misoprostol	Diarrhea Dizziness
537	36 Year	Female	Misoprostol	Diarrhea
538	25 Year	Female	Misoprostol	Diarrhea
539	24 Year	Female	Misoprostol	Diarrhea, Shivering, Nausea
540	26 Year	Female	Misoprostol	Diarrhea

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
541	12 Month	Female	MMR vaccine	Rash
542	33 Year	Female	Mometasone	Dermatitis seborrheic
543	NA	Female	Montelukast	Weight gain
544	NA	Female	Montelukast	Muscular pain
545	17 Year	Male	Morphine	Confusion, Periorbital hematoma
546	NA	Female	Moxifloxacin	Shortness of breath Itchy rash
547	NA	Male	Multivitamins	Edema
548	63 Year	Male	Mycophenolate, Sirolimus	CMV infection BK virus infection
549	52 Year	Female	Nivolumab	Hypothyroidism
550	47 Year	Female	Nivolumab	Transaminitis
551	62 Year	Female	Obinutuzumab	Shortness of breath
552	23 Year	Male	Olanzapine	Yawning excessive, Flu
553	20 Year	Male	OLANZAPINE	Rash
554	37 Year	Female	Olanzapine	Weight gain
555	47 Year	Male	Olanzapine	Increased appetite
556	19 Year	Male	Olanzapine	Over sedation
557	NA	Male	Omeprazole	Heartburn
558	NA	Female	omeprazole	Rash
559	70 Year	Female	Omeprazole	Headache
560	70 Year	Female	Omeprazole	Gastritis
561	NA	Male	Omeprazole	Allergy
562	60 Year	Male	Omeprazole	Palpitation, Sweating
563	33 Year	Male	Omeprazole	Allergy
564	45 Year	Female	Osimertinib	Disease progression NOS
565	45 Year	Female	Osimertinib	Disease progression NOS
566	53 Year	Male	Oxaliplatin	Fatigue
567	57 Year	Female	Oxaliplatin	Itching
568	35 Year	Female	Oxaliplatin	Shivering
569	NA	Female	Oxazepam	Fatigue
570	63 Year	Female	Paclitaxel	Pulmonary toxicity
571	75 Year	Female	Paclitaxel	Pneumocystis carinii pneumonia

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
572	29 Year	Female	Pantoprazole	Type II hypersensitivity , Maculopapular rash, Itching
573	21 Year	Female	paracetamol	Asthma
574	3 Year	Female	Paracetamol	Rash
575	43 Year	Female	Paracetamol	Allergy
576	4 Year	Male	Paracetamol overdose	Acetaminophen increased
577	57 Year	Male	Pazopanib, Esomeprazole, Granisetron	Nausea, Vomiting
578	13 Month	Female	PCV13	Injection site swelling
579	9 Year	Male	PEG-Asparaginase	Anaphylaxis
580	16 Year	Male	PEG-Asparaginase	Hyperglycemia
581	50 Year	Male	PEG-Asparaginase	Hepatic function abnormal NOS
582	60 Year	Male	Pemetrexed	Hyperkalemia
583	6 Month	Male	Pentavalent vaccine	Convulsions
584	6 Month	Female	Pentavalent vaccine	Swelling
585	42 Year	Female	Perindopril/amlodipine	Allergy
586	36 Year	Female	Pethidine	Vomiting
587	4 Year	Male	Phenoxymethylpenicilin	Skin rash
588	80 Year	Male	Phenytoin	Skin rash
589	7 Month	Male	Piperacillin/Tazobactam	Itching all over
590	31 Year	Female	Piperacillin/Tazobactam	Itching
591	35 Year	Male	Piperacillin/Tazobactam	Acute anaphylaxis
592	84 Year	Male	Piperacillin/Tazobactam	Stevens-Johnson syndrome
593	63 Year	Female	Piperacillin/Tazobactam	DRESS syndrome
594	69 Year	Male	Piperacillin/Tazobactam	Chest tightness
595	32 Year	Male	Piperacillin/Tazobactam	Tachycardia
596	25 Year	Female	Piperacillin/Tazobactam	Erythematous rash
597	32 Year	Male	Piperacillin/Tazobactam	Seizure
598	22 Month	Female	Potassium Chloride	Rash
599	22 Month	Female	Potassium Chloride	Rash
600	10 Year	Female	Potassium Chloride	Dizziness
601	7 Year	Male	Prednisolone	Fainting
602	50 Year	Female	Prednisolone	Hematuria
603	50 Year	Female	Prednisolone	Weight gain

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
604	76 Year	Male	Prednisolone	Nausea
605	17 Year	Male	Prednisolone	Hyperglycemia
606	29 Year	Male	Procyclidine	Nausea
607	42 Year	Female	Procyclidine	Blood pressure
608	60 Year	Female	Propranolol	Bradycardia
609	9 Month	Female	Propranolol	Lethargy
610	60 Year	Female	Propranolol	Palpitation
611	28 Year	Male	Pseudoephedrine/Tripolidine	Sedation
612	4 Year	Male	Pseudoephedrine/Tripolidine	Hyperactivity
613	64 Year	Male	Ramucirumab, Paclitaxel	Neuropathy, Subconjunctival hemorrhage Deranged liver function tests Microalbuminuria, Fatigue, Hypothyroidism Epistaxis
614	60 Year	Female	Ranitidine	Abdominal colic
615	60 Year	Female	Ranitidine	Rash
616	60 Year	Female	Ranitidine	Muscle ache
617	NA	Female	Ranitidine	Rash
618	48 Year	Female	Ranitidine	Dizziness
619	NA	Female	Ranitidine	Constipation
620	NA	Female	Ranitidine	Skin rash
621	71 Year	Female	Ranitidine	Fatigue
622	48 Year	Male	Ranitidine	Dry mouth
623	28 Year	Female	Ranitidine	Skin rash
624	32 Year	Female	Ranitidine	Itching
625	32 Year	Female	Ranitidine	Itching
626	43 Year	Male	Ranitidine	Diarrhea
627	51 Year	Female	Regorafenib	Hand and foot syndrome
628	63 Year	Male	Reteplase	Haemoptysis
629	49 Year	Male	Reteplase, Heparin	Haematemesis
630	23 Year	Male	Rifampicin	Serum alkaline phosphatase elevated
631	74 Year	Male	Rifampin	Hepatotoxicity
632	5 Year	Male	Risperidone	CBC abnormal
633	10 Year	Male	Risperidone	Sleep excessive
634	47 Year	Male	Risperidone	Syndrome dyskinetic

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
635	NA	Female	Rituximab	Hoarseness of voice
636	15 Year	Female	Rituximab	Tachycardia
637	38 Year	Female	Rituximab	Epigastric pain
638	22 Year	Male	Rituximab	Rash face
639	16 Year	Male	Rituximab	Transaminitis
640	44 Year	Female	Rituximab	Neutropenia
641	16 Year	Male	Rituximab	Hypertension
642	16 Year	Female	Rituximab	Febrile neutropenia
643	50 Year	Male	Rituximab	Febrile neutropenia
644	36 Year	Female	Rituximab	Cough, Throat irritation, Shortness of breath
645	NA	NA	Rituximab, Treosulfan, Thiotepa Fludarabine, Antithymocyte Immunoglobulin (rabbit)	Gram-negative sepsis Multi organ failure
646	NA	Female	Rituximab, Treosulfan, Thiotepa, Fludarabine Antithymocyte Immunoglobulin (rabbit)	CMV retinitis, Retinal infiltrates, Viremia
647	NA	NA	Rituximab, Treosulfan, Thiotepa, Flu darabine Antithymocyte immunoglobulin (rabbit)	Stenotrophomonas sepsis Multi organ failure
648	NA	NA	Rituximab, Treosulfan, Thiotepa, Fludarabine Antithymocyte Immunoglobulin (rabbit)	Klebsiella sepsis, Multi organ failure
649	NA	NA	Rituximab, Treosulfan, Thiotepa, Fludarabine Antithymocyte Immunoglobulin (rabbit) Co-trimoxazole	Pseudomonal sepsis, Multi organ failure
650	NA	NA	Rituximab, Treosulfan, Thiotepa, Fludarabine Antithymocyte Immunoglobulin (rabbit) Sulfamethoxazole; Trimethoprim	Heart failure, Pulmonary edema, Acute lung injury, Gastrointestinal hemorrhage Candidemia, Pneumocystis carinii pneumonia, Cytomegalovirus enteritis
651	73 Year	Male	Rivaroxaban	Palpitation
652	91 Year	Male	Rivaroxaban	Palpitation
653	73 Year	Male	Rivaroxaban	Palpitation
654	57 Year	Male	Salbutamol	Heartburn



SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
655	10 Day	Male	scopolamine	Tachycardia
656	69 Year	Female	Sitagliptin	Cough
657	53 Year	Female	Sitagliptin	Hypoglycemia
658	55 Year	Female	Sitagliptin	Skin rash
659	30 Year	Male	Sitagliptin	Headache
660	31 Year	Female	Sodium acid phosphate	Itching
661	1 Day	Male	Sodium valproate	High arched palate, Flat philtrum
662	72 Year	Female	Sodium valproate	Mood change, Restlessness, Visual hallucinations, Disorientated
663	40 Year	Female	Sodium valproate	Weight gain
664	40 Year	Female	Sodium valproate, Levetiracetam	Tremor
665	NA	Male	Somatropin	Subtherapeutic response
666	11 Year	Male	Somatropin	HbA1C increased
667	NA	Male	Somatropin	Pain during injection
668	NA	Male	Somatropin	Headache
669	50 Year	Female	Sorafenib	Rash
670	51 Year	Female	Sorafenib	Allergic reaction
671	11 Day	Male	Spirolactone	Renal function abnormal
672	73 Year	Male	Spirolactone	Hyponatremia
673	39 Year	Female	Sterile alcohol swabs	Skin coloring
674	37 Year	Male	Stevia rebaudiana, Hibiscus sabdariffa	Cathartic laxative habituation Tachycardia
675	38 Year	Female	Sulfasalazine	Eye swelling
676	NA	Female	Sulfasalazine, Cefdinir	Ulcers aphthous oral, Stevens Johnson type reaction
677	40 Year	Female	Tacrolimus	Hemolysis
678	53 Year	Female	Tigecycline	Hepatotoxicity
679	11 Year	Female	Tocilizumab	Itching
680	4 Year	Male	Tolterodine	Fecal incontinence
681	NA	Female	Topiramate	Uric acid high
682	54 Year	Female	Tramadol	Itching - generalised
683	44 Year	Female	Tramadol	Dizziness, Vomiting
684	NA	Female	Tramadol	Rash

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
685	39 Year	Female	Trastuzumab	Heart failure
686	16 Year	Female	Trientine Dihydrochloride	Abdominal pain, Mouth ulceration
687	56 Year	Male	Trifluridine/Ttipiracil	Pancytopenia
688	15 Year	Female	Valaciclovir	Rash
689	66 Year	Female	Valsartan	Persistent dry cough
690	69 Year	Female	Valsartan	Asthmatic attack
691	56 Year	Female	Valsartan	Drowsiness
692	72 Year	Female	Valsartan	Coughing
693	61 Year	Female	Valsartan	Itching
694	85 Year	Female	Valsartan	Tremor
695	NA	Female	Valsartan	Cough
696	60 Year	Female	Valsartan	Dizziness
697	27 Year	Female	Vancomycin	Skin reaction
698	80 Year	Female	Vancomycin	Red Man Syndrome (RMS)
699	53 Year	NA	Vancomycin	Itching
700	29 Year	Female	Vancomycin	Skin rash
701	23 Year	Male	Vancomycin	Itching
702	56 Year	Female	Vancomycin	Impaired renal function
703	24 Year	Male	Vancomycin	Itching
704	69 Year	Female	Vancomycin	Facial rash
705	21 Year	Female	Vancomycin	Acute kidney injury
706	11 Year	Male	Vancomycin	RMS, Pain burning
707	35 Year	Female	Varicella vaccine	Skin rash, Fever
708	54 Year	Male	Vemurafenib	Hypersensitivity
709	23 Year	Male	Venlafaxine	Yawning excessive
710	32 Year	Female	Vilanterol/fluticasone furoate	Dry cough
711	60 Year	Male	Vildagliptin / Metformin	Dizziness
712	43 Year	Female	Vincristine	Mucositis
713	50 Year	Male	Vincristine	Hypotension
714	44 Year	Female	Vincristine	Mucositis
715	NA	Male	Voriconazole	Cardiotoxicity
716	43 Year	Female	Voriconazole	Hallucination visual
717	43 Year	Female	Voriconazole	Hypercalcemia
718	56 Year	Male	Warfarin	Acute subdural hematoma, Raised INR

SR No	Age at onset of reaction	Sex	Drug name (WHODrug)	Reaction / event (MedDRA)
719	70 Year	Male	Warfarin	Haemoptysis, Raised INR, Ecchymosis
720	56 Year	Male	Warfarin	International normalized ratio increased
721	50 Year	Male	Warfarin	Epistaxis
722	60 Year	Female	Zoledronic acid	Osteonecrosis of jaw